Copeland, Paul M

Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses

Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry

Schizophrenia research and treatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 288

Adrenocortical carcinoma: contrast washout characteristics on CT

Slattery, J. M. A., Blake, M. A., Kalra, M. K., Misdraji, J., Sweeney, A. T., Copeland, P. M., Mueller, P. R., & Boland, G. W. (2006) · American Journal of Roentgenology

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 81

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism

Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research

Schizophrenia research and treatmentTryptophan and brain disorders

Cited by 67

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

Wexler, D. J., de Boer, I. H., Ghosh, A., Younes, N., Bebu, I., Inzucchi, S. E., McGill, J. B., Mudaliar, S., Schade, D., Steffes, M. W., et al. (2023) · JAMA Internal Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 39

Two Cases of Therapeutic Failure Associated with Levothyroxine Brand Interchange

Copeland, P. M. (1995) · Annals of Pharmacotherapy

Thyroid Disorders and TreatmentsPharmaceutical Quality and Counterfeiting

Cited by 14